Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lots of new Deals just announced
09/04/2007 (08:47 ET) DVNTF: Signs Agreement with AHG Health Group - Knobias
http://www.knobias.com/story.htm?eid=3.1.2c7ca96f6f2b367523be842dd6fe16c22b85c71a0caedfab2e1f2909778....
Tuesday , September 04, 2007 08:47ET
By Jay Everitt, jeveritt@knobias.com
Diversinet Corp. (DVNTF) announced it has successfully signed a License and Revenue Share Agreement with AHG Health Group, Inc. ("AHG"), a wholly owned subsidiary of Hospital Service Association of Northeastern Pennsylvania to cross license certain software and to share revenues from the secure mobile access to personal health information.
Under the three year agreement, Diversinet will receive U.S.$2 million annually as a minimum commitment from AHG. Diversinet and AHG will be initially focusing on Blue Cross Blue Shields Association member plans and other customers in the mobile personal health record market in the United States.
09/04/2007 (08:46 ET) Diversinet Closes $5 Million Strategic Investment from Blue Cross of Northeastern Pennsylvania - Canada NewsWire
http://www.knobias.com/story.htm?eid=3.1.6414c03607054a86a97ba7ba7b78175924d75387f554f135413968357f1...
Diversinet Closes $5 Million Strategic Investment from Blue Cross of Northeastern Pennsylvania
Tuesday , September 04, 2007 08:46ET
TORONTO, Sep. 4, 2007 (Canada NewsWire via COMTEX) -- Diversinet Corp. (OTCBB: DVNTF), a leading provider of wireless data application and security infrastructure products and services, today announced it has successfully closed U.S.$5.0 million in new funding through a private placement with Hospital Service Association of Northeastern Pennsylvania, d/b/a Blue Cross of Northeastern Pennsylvania ("BCNEPA").
Funding will be provided through the sale and issue of 6,756,757 shares by way of private placement at U.S.$0.74 per share for gross proceeds of U.S.$5,000,000. Under the funding agreement, William C. Reed, executive vice president for BCNEPA will join the Diversinet Board. The company will use this funding for working capital purposes and general operations.
"We welcome Bill to the Board and his experience gained in the health care industry will be invaluable as Diversinet moves forward," said Albert Wahbe, CEO and Chairman of Diversinet.
Prior to joining BCNEPA, Mr. Reed held numerous management positions in healthcare provider organizations including Gentiva Health Services, Quantum Health Resources, and Geisinger Health System. Mr. Reed received his Bachelor of Science in business administration from Drexel University and his Master of Science in computer science from Rutgers University.
After completion of the private placement, there are 41,742,075 shares issued and outstanding, and 54,121,972 shares on a fully diluted basis. The common shares cannot be re-sold in the public markets until a registration statement has been filed and declared effective by the U.S. Securities and Exchange Commission. This press release does not represent an offer to buy or to sell any securities. No investment banker commissions were paid in connection with this transaction.
09/04/2007 (08:46 ET) Diversinet Signs a 3 year License & Revenue Share Agreement with AllOne Health Group, Inc. - Canada NewsWire
09/04/2007 (08:45 ET) Diversinet Closes $5 Million Strategic Investment from Blue Cross of Northeastern Pennsylvania - PR Newswire
09/04/2007 (08:45 ET) Diversinet Signs a 3 year License & Revenue Share Agreement with AllOne Health Group, Inc. - PR Newswire
Last I knew, Judge Cooper had to rule before the next step.
In Addition the # of shares MA dumped is greater than the total # of shares of the Float. What happens? Dilution
Well that may just be the case since the Grandfather Rule was just published last week.
http://www.sec.gov/rules/final/2007/34-56212.pdf
Yes, I haven't seen that type of Huge Volume for months...like since Dec. 2006
Yes, and tanks on low volume also which happened after the last run.
It's on the NSS list..Why? Is a placement being done and they are short selling up front?
What's the true Float and where are the shares being added into the Float coming from?
What iphone info? Could you expound upon? May be good buying opportunity but would like more insight into iphone first.
Who else has confirmed the share structure with the T/A & the company?
Will call myself.
The last filing as of May 10, 2007 for IVGR:
The number of shares of common stock outstanding as of May 10, 2007 was 60,793,488.
The last filing as of May 10, 2007 for IVGR:
The number of shares of common stock outstanding as of May 10, 2007 was 60,793,488.
Call the Transfer Agent yourself is my recommendation. Don't go by B.S. posted on the board.
.0071 x .0073 IVGR was Oversold and Naked Shorted after the R/S which would have been equivalent to .04. Has Room to Run. Floor in at .007 IMO.
O.K. Wally World..LOL.. Some may not want to leave their home and pay to drive to Wally World. It's more expensive to drive there with the cost of gas and wear & tear on vehicle and most importantly...time is money. Just to save a couple $$ isn't worth it to many. This isn't a big ticket item. I'd pay for the convenience!
No, but that's the trading game.
There was already more volume yesterday so the volume comment is lame. It's called flipping umpteen times in a day.
Thanks for all the Music in the past!
The Snitch should occupy their time elsewhere. Very disappointing that the tunes are no longer available.
I believe .04 was the equivalent price that this stock should have opened up at after the R/S.
This company did a R/S awhile back and has yet to recoup before the R/S. My guess is those Naked Short #'s are higher and now have to be reconciled with the recent SEC rule making.
Like I said this still hasn't made it back to even before the R/S and has room to RUN yet. Brokers and MM's have to shore up.
Yes, but was Michelle Shearer Short when she bought Ed Hayter's shares?
I agree. Only some of the sting could be taken away from IBCX.. I would still have yet to break even after the 1:1000 RS if I would have held.
Thanks! I'll know to avoid PRSU.!
So Is Hayter Gone and in Jail? Is that the Reason for the Run?
They were Rolling Out to 7-11's last yr. Quick place to drop by and pick up an Iced Coffee while getting gas, munchies, etc. I'm not sure what their total # of 7-11's they're in now.
JAVO.. their specialty iced coffee for summer is always a hit
MHII What's the Authorized? What's listed on Nevada website. This is nothing more than Bailey and Ternes filling their pockets.
Anybody Notice AJW in the Cookie Jar Here? Is this the Same AJW?
https://esos.state.nv.us/SOSServices/AnonymousAccess/CorpSearch/corpActions.aspx?lx8nvq=22YU6GiDL51xH9BY 35qlrQ%253d%253d&CorpName=MARSHALL+HOLDINGS+INTERNATIONAL%2c+INC.
Document Number: 20060742465-76 # of Pages: 1
File Date: 11/20/2006 Effective Date: 12/04/2006
(No Notes for this action)
Action Type: Stock Split
Document Number: 20060554036-91 # of Pages: 1
File Date: 08/29/2006 Effective Date:
(No Notes for this action)
Action Type: Annual List
Document Number: 20060551395-76 # of Pages: 2
File Date: 08/29/2006 Effective Date:
(No Notes for this action)
Action Type: Annual List
Document Number: 20050460616-00 # of Pages: 1
File Date: 10/05/2005 Effective Date:
(No Notes for this action)
Action Type: Resident Agent Address Change
Document Number: C6214-1993-021 # of Pages: 1
File Date: 01/21/2005 Effective Date:
FLORIAN R TERNES
3095 E PATRICK LANE LAS VEGAS NV 89120 RAA
Action Type: Amendment
Document Number: C6214-1993-020 # of Pages: 7
File Date: 01/18/2005 Effective Date:
CERTIFICATE OF DESIGNATION FILED DESIGNATING 1OO,OOO,OOO SHARES AS SERIES B
PREFERRED STOCK. (7)PGS MLJ
Action Type: Amendment
Document Number: C6214-1993-019 # of Pages: 1
File Date: 11/09/2004 Effective Date:
AMENDMENT TO CERTIFICATE OF DESIGNATION FILED 10-1-02 INCREASING FROM
200,000 SHARES SERIES A PREFERRED TO 100,000,000 SHARES SERIES A PREFERRED.
(1) PG. DEG
Action Type: Amendment
Document Number: C6214-1993-018 # of Pages: 1
File Date: 10/04/2004 Effective Date:
CAPITAL STOCK WAS 225,000,000 @ .001 = $225,000. JEP
CERTIFICATE OF AMENDMENT FILED AMENDING ARTICLE IV, STOCK.
EFF DATE OF 10/4/04. (1)PG. JEP
Action Type: Amendment
Document Number: C6214-1993-017 # of Pages: 2
File Date: 08/26/2004 Effective Date:
CAPITAL STOCK WAS 25,200,000,000 @ .001 = $25,200,000 DEG
CERTIFICATE OF CHANGE PURSUANT TO NRS 78.209 FILED. (2) PG. DEG
Action Type: Amendment
Document Number: C6214-1993-016 # of Pages: 3
File Date: 06/25/2004 Effective Date:
CAPITAL STOCK WAS 25,001,000,000 AT .001 PER SHARE CHM
CERTIFICATE OF AMENDMENT FILED AMENDING ARTICLE IV - STOCK. (3)PGS CHM
Action Type: Amendment
Document Number: C6214-1993-015 # of Pages: 2
File Date: 06/23/2004 Effective Date:
CERTIFICATE OF AMENDMENT FILED AMENDING ARTICLE IV (LANGUAGE).
(1) PG. DEG
Action Type: Annual List
Document Number: C6214-1993-002 # of Pages: 1
File Date: 05/26/2004 Effective Date:
List of Officers for 2004 to 2005
Action Type: Annual List
Document Number: C6214-1993-022 # of Pages: 1
File Date: 05/20/2003 Effective Date:
(No Notes for this action)
Action Type: Amendment
Document Number: C6214-1993-014 # of Pages: 9
File Date: 10/01/2002 Effective Date:
CERTIFICATE OF DETERMINATION FILED DESIGNATING 200,000 SHARES OF SERIES A
CONVERTIBLE PREFERRED STOCK. 9 PGS. RAF
Action Type: Resident Agent Change
Document Number: C6214-1993-013 # of Pages: 1
File Date: 07/09/2002 Effective Date:
MATTHEW H SWAN
9005 WEST SAHARA LAS VEGAS NV 89117 RAA
Action Type: Amendment
Document Number: C6214-1993-012 # of Pages: 1
File Date: 05/31/2002 Effective Date:
CAPITAL STOCK WAS 1,001,000,000@ .001 = 1,001,000 AJW
CERTIFICATE OF AMENDMENT FILED AMENDING ONLY THE COMMON STOCK. (1PG)($10,050)
AJW
Action Type: Resident Agent Change
Document Number: C6214-1993-011 # of Pages: 1
File Date: 04/29/2002 Effective Date:
MATTHEW SWAN
500 E CHEYENNE AVENUE NORTH LAS VEGAS NV 89030 RAA
Action Type: Amendment
Document Number: C6214-1993-010 # of Pages: 1
File Date: 01/03/2002 Effective Date:
CAPITAL STOCK WAS 21,000,000 @ .001 RAF
$475 1 PG. RAF
Action Type: Annual List
Document Number: C6214-1993-023 # of Pages: 1
File Date: 05/21/2001 Effective Date:
(No Notes for this action)
Action Type: Annual List
Document Number: C6214-1993-025 # of Pages: 1
File Date: 06/06/2000 Effective Date:
(No Notes for this action)
Action Type: Amendment
Document Number: C6214-1993-009 # of Pages: 5
File Date: 06/24/1999 Effective Date:
AMENDED AND RESTATED ARTICLES FILED, DELETING ARTICLE 5,6,9,10,11, AND ADDED 12
5PGS AJW Action Type: Annual List
Document Number: C6214-1993-024 # of Pages: 1
File Date: 07/14/1998 Effective Date:
(No Notes for this action)
Action Type: Merger
Document Number: C6214-1993-008 # of Pages: 2
File Date: 05/14/1998 Effective Date:
ARTICLES OF MERGER FILED MERGING HALI SALES CORP., A (DE) CORPORATION NOT
QUALIFIED IN NEVADA, INTO THIS CORPORATION. (2)PGS. MMR
Action Type: Amendment
Document Number: C6214-1993-007 # of Pages: 2
File Date: 05/01/1998 Effective Date:
CAPITAL STOCK WAS 2,500 NO PAR. DMF
BREAKDOWN OF SHARES: 20 MILLION COMMON AND 1 MILLION PREFERRED. (2)PGS. DMF
Action Type: Resident Agent Change
Document Number: C6214-1993-006 # of Pages: 1
File Date: 01/20/1998 Effective Date:
MARK S. COOLMAN
500 E. CHEYENNE AVE NO. LAS VEGAS NV 89030 MJM
Action Type: Amendment
Document Number: C6214-1993-005 # of Pages: 3
File Date: 07/09/1996 Effective Date:
CERTIFICATE OF AMENDMENT FILED AMENDING ARTICLE FOURTH - 2,250 VOTING COMMON
STOCK & 250 NON VOTING COMMON STOCK BOTH AT NO PAR; AMENDING ARTICLE FIFTH -
DIRECTORS; AMENDING ARTICLES NINTH & ELEVENTH. (3) PGS. PMI
Action Type: Resident Agent Change
Document Number: C6214-1993-004 # of Pages: 1
File Date: 01/23/1995 Effective Date:
CORPORATION SERVICE COMPANY
530 SOUTH FOURTH STREET LAS VEGAS NV 89101 SRH
Action Type: Amendment
Document Number: C6214-1993-003 # of Pages: 1
File Date: 01/09/1995 Effective Date:
REINSTATED - REVOKED 4/1/94 ALH
Action Type: Articles of Incorporation
Document Number: C6214-1993-001 # of Pages: 3
File Date: 05/26/1993 Effective Date:
(No Notes for this action)
What do you make of the VP leaving? I'm assuming it's for a CEO or better position elsewhere. I don't think one would agree to a 6 month extended Contract/Consultant if things were different.
http://biz.yahoo.com/e/070522/agen8-k.html
I was wondering the same. Do you think they are running for this:?
http://www.sec.gov/Archives/edgar/data/944522/000095013607003493/file1.htm
$60,000,000 Principal Amount of 7.75% Convertible Senior Notes due February 15, 2012
31,249,980 Shares of Common Stock Issuable to Noteholders upon Conversion of such Notes
7,800,000 Shares of Common Stock Issuable to Warrantholders upon Exercise of Warrants
8,540,333 Shares of Common Stock Issuable as Make-Whole Payments under such Notes
8,205,882 Shares of Common Stock Issuable in Payment of Interest on such Notes
We issued the notes offered by this prospectus in a private placement in February 2007. This prospectus will be used by the selling securityholders identified in this prospectus to resell their notes and the common stock issuable upon conversion of the notes. This prospectus also relates to the potential issuance by us of shares of common stock to the holders of notes in payment of interest on the notes and in payment of certain make-whole premiums in the event of an automatic conversion of the notes or the occurrence of a fundamental change. This prospectus also relates to the offer and sale by the selling securityholders of shares of common stock issuable upon exercise of certain warrants to purchase shares of our common stock issued to them in the private placement.
The process by which the selling securityholders will sell or distribute their notes or common stock is described in this prospectus under the heading ‘‘Plan of Distribution.’’ Sales may be at fixed or negotiated prices determined at the time of sale. We will not receive any proceeds from this offering other than the exercise price payable to us upon the exercise of the warrants, if any.
The notes are our senior unsecured obligations: (i) junior in right of payment to our future secured indebtedness to the extent of the value of the collateral securing such indebtedness; (ii) equal in right of payment to our future senior unsecured indebtedness; (iii) senior in right of payment to our existing and future subordinated indebtedness; and (iv) structurally subordinated to any indebtedness or other liabilities of our subsidiaries, each subject to certain limitations. We will pay interest on the notes on February 15 and August 15 of each year. The first interest payment will be made on August 15, 2007. We may pay interest in cash, registered shares of our common stock or some combination of cash and registered shares of our common stock.
Subject to certain conditions described in this prospectus:
• you may convert the notes at an initial conversion rate of 520.833 shares per each $1,000 principal amount of notes – equivalent to an initial conversion price of approximately $1.92 per share;
ZHNE - Ditto was just seeing all the insider buys and news posted http://www.knobias.com/story.htm?eid=3.1.2f9b58fcd5d5e4f0136d83e00e1a1c4e3cb4a1988686066bfca6c1377b5...
I don't have a subscription to the WSJ but Knobias verifies your statement.
http://www.knobias.com/individual/public/quote.htm?ticker=agen
05/22/2007 (07:05 ET) Healthcare News (Jefferies) - 3rd Party Opinions
05/22/2007 (06:07 ET) AGEN: mentioned in today's Wall Street Journal - Knobias
05/22/2007 (03:45 ET) OTCPicks.com: Daily Market Movers Digest Report for Tuesday May 22nd, AGEN, WTVI, FMLY, ARSC, ARTX - M2 Communications
I don't have a subscription to the WSJ but Knobias verifies your statement.
http://www.knobias.com/individual/public/quote.htm?ticker=agen
05/22/2007 (07:05 ET) Healthcare News (Jefferies) - 3rd Party Opinions
05/22/2007 (06:07 ET) AGEN: mentioned in today's Wall Street Journal - Knobias
05/22/2007 (03:45 ET) OTCPicks.com: Daily Market Movers Digest Report for Tuesday May 22nd, AGEN, WTVI, FMLY, ARSC, ARTX - M2 Communications
From the CEO's Blog (March 30 but still relevant):
http://www.antigenics.com/news/ceoblog/2007/0330.html
If the outcome of this analysis (to be announced in early June 2007) is positive, we expect to request a pre–biologic license application (BLA) meeting with the FDA to determine the possibility of filing for approval. Concurrently, we will also explore the approval or conditional approval of Oncophage in renal cell carcinoma in other major geographies, including Russia, Europe, Canada and Japan.
AGEN : Thanks for the chart.. I expect it to be a Gapper too.
Agen Here's the Update
Antigenics Says Drug Cut Relapse Risk; Shares Rise (Update1)
http://www.bloomberg.com/apps/news?pid=conewsstory&refer=conews&tkr=AGEN:US&sid=a07MazNp....
Antigenics Says Drug Cut Relapse Risk; Shares Rise (Update1)
By Luke Timmerman
May 21 (Bloomberg) -- Antigenics Inc., a developer of drugs that stimulate the immune system, said its most advanced experimental medicine reduced the risk of relapse for a subgroup of people with kidney cancer. Shares rose as much as 43 percent.
In a study of patients who had surgery to remove kidney tumors, the drug Oncophage stopped the disease from coming back for 4.2 years, compared with 2.5 years for patients who didn't get the medicine, according to data presented at the American Urological Association meeting in Anaheim, California. The people on Oncophage had a 45 percent lower risk of relapse.
While not all patients benefited, positive results were found in about 60 percent of the 604 cases. Such so-called subset analyses are usually rejected by U.S. regulators, so the company said it may seek clearance to sell the drug in Europe, Canada and Russia. If approved, Oncophage would be the first product for New York-based Antigenics, and a new therapy for a disease that strikes 50,000 people in Europe.
``The fact that this agent is active and it's non-toxic is very compelling to patients,' said the lead investigator, Christopher Wood, a urologist at the University of Texas M.D. Anderson Cancer Center in Houston.
Antigenics' shares rose 68 cents, or 27 percent, to $3.22 at 12:15 p.m. New York time in Nasdaq Stock Market composite trading, after touching $3.62 a share. The shares have risen 64 percent in the last 12 months.
Lower Relapse Risk
The study was conducted from 2000 to 2005. It found that Oncophage offered a 45 percent lower risk of cancer relapse than seen in patients who had standard observation. The benefit was seen in a group of 362 patients with intermediate risk of relapse. It wasn't found in patients with a high risk of relapse, according to a scoring system from the Eastern Cooperative Oncology Group, an association of cancer physicians.
It was ``rewarding' to see benefits in a subset of patients, Wood said, adding it was ``disappointing' the drug didn't help all patients.
The company doesn't have complete data on whether Oncophage prolongs lives for patients with intermediate risk. Antigenics expects to have those results in 12 to 18 months, because that's how long people typically live after relapse, said Garo Armen, Antigenics' chief executive officer.
After 17 months of follow-up from the end of the study, one patient with intermediate risk has died in the Oncophage group, compared with 13 deaths among patients who didn't get the drug, the company said. Side effects were minimal from injection-site reactions, the company said.
No Anomaly
``If this benefit were an anomaly, you would think it would fade over time,' Armen said in a telephone interview. ``If it were real, you would expect it to remain. The benefit we saw in a very large patient population was maintained over time.'
Antigenics' therapy is a so-called ``cancer vaccine' that stimulates the immune system to fight cancer cells. It is designed to be personalized, by cutting out a portion of a patient's tumor and extracting a key protein inside tumor cells.
The tumors are chopped up, the proteins are separated by a machine, and injected back into the patient to ``teach' the immune system to recognize hallmarks of cancer and fight them. Patients get their personalized vaccine three weeks after their tumors are removed.
Armen said the U.S. Food and Drug Administration has frowned on drugs that depend on subset analyses. Armen said such analyses can be ``fishing expeditions' by companies searching for something positive from a failed study. He said he isn't hopeful the agency will view his data any differently.
Intermediate Risk
If the company were forced to do another trial that looked specifically at intermediate risk patients, it would take an additional five to six years and wouldn't be practical, Armen said. Antigenics couldn't have designed the trial differently when it started in 2000, he said, because the intermediate scoring system didn't exist then.
It makes sense that Oncophage might work better in patients with a healthier prognosis, because it can take months for Oncophage to recharge the immune system, and the sickest patients might not have that much time, Armen said.
Antigenics was founded in 1994 and had an accumulated deficit of $470.5 million through March 31, according to the company's first-quarter earnings report to the U.S. Securities and Exchange Commission.
The company's stock has mirrored the ups and downs of Seattle-based Dendreon Corp., another developer of immune- stimulating therapies for cancer. Antigenics stock rose 12 percent on March 30, after Dendreon received a positive recommendation from an FDA advisory panel.
Antigenics shares then dropped 12 percent on May 9, when the FDA asked Dendreon to provide more information to show its prostate cancer treatment is effective.
To contact the reporter on this story: Luke Timmerman in San Francisco ltimmerman@bloomberg.net .
Last Updated: May 21, 2007 12:19 EDT
Email this article Printer friendly format
Advertisement: A surprising prediction by Ken Fisher - Get his forecast here!
Agen Here's the Update
Antigenics Says Drug Cut Relapse Risk; Shares Rise (Update1)
http://www.bloomberg.com/apps/news?pid=conewsstory&refer=conews&tkr=AGEN:US&sid=a07MazNp....
Antigenics Says Drug Cut Relapse Risk; Shares Rise (Update1)
By Luke Timmerman
May 21 (Bloomberg) -- Antigenics Inc., a developer of drugs that stimulate the immune system, said its most advanced experimental medicine reduced the risk of relapse for a subgroup of people with kidney cancer. Shares rose as much as 43 percent.
In a study of patients who had surgery to remove kidney tumors, the drug Oncophage stopped the disease from coming back for 4.2 years, compared with 2.5 years for patients who didn't get the medicine, according to data presented at the American Urological Association meeting in Anaheim, California. The people on Oncophage had a 45 percent lower risk of relapse.
While not all patients benefited, positive results were found in about 60 percent of the 604 cases. Such so-called subset analyses are usually rejected by U.S. regulators, so the company said it may seek clearance to sell the drug in Europe, Canada and Russia. If approved, Oncophage would be the first product for New York-based Antigenics, and a new therapy for a disease that strikes 50,000 people in Europe.
``The fact that this agent is active and it's non-toxic is very compelling to patients,' said the lead investigator, Christopher Wood, a urologist at the University of Texas M.D. Anderson Cancer Center in Houston.
Antigenics' shares rose 68 cents, or 27 percent, to $3.22 at 12:15 p.m. New York time in Nasdaq Stock Market composite trading, after touching $3.62 a share. The shares have risen 64 percent in the last 12 months.
Lower Relapse Risk
The study was conducted from 2000 to 2005. It found that Oncophage offered a 45 percent lower risk of cancer relapse than seen in patients who had standard observation. The benefit was seen in a group of 362 patients with intermediate risk of relapse. It wasn't found in patients with a high risk of relapse, according to a scoring system from the Eastern Cooperative Oncology Group, an association of cancer physicians.
It was ``rewarding' to see benefits in a subset of patients, Wood said, adding it was ``disappointing' the drug didn't help all patients.
The company doesn't have complete data on whether Oncophage prolongs lives for patients with intermediate risk. Antigenics expects to have those results in 12 to 18 months, because that's how long people typically live after relapse, said Garo Armen, Antigenics' chief executive officer.
After 17 months of follow-up from the end of the study, one patient with intermediate risk has died in the Oncophage group, compared with 13 deaths among patients who didn't get the drug, the company said. Side effects were minimal from injection-site reactions, the company said.
No Anomaly
``If this benefit were an anomaly, you would think it would fade over time,' Armen said in a telephone interview. ``If it were real, you would expect it to remain. The benefit we saw in a very large patient population was maintained over time.'
Antigenics' therapy is a so-called ``cancer vaccine' that stimulates the immune system to fight cancer cells. It is designed to be personalized, by cutting out a portion of a patient's tumor and extracting a key protein inside tumor cells.
The tumors are chopped up, the proteins are separated by a machine, and injected back into the patient to ``teach' the immune system to recognize hallmarks of cancer and fight them. Patients get their personalized vaccine three weeks after their tumors are removed.
Armen said the U.S. Food and Drug Administration has frowned on drugs that depend on subset analyses. Armen said such analyses can be ``fishing expeditions' by companies searching for something positive from a failed study. He said he isn't hopeful the agency will view his data any differently.
Intermediate Risk
If the company were forced to do another trial that looked specifically at intermediate risk patients, it would take an additional five to six years and wouldn't be practical, Armen said. Antigenics couldn't have designed the trial differently when it started in 2000, he said, because the intermediate scoring system didn't exist then.
It makes sense that Oncophage might work better in patients with a healthier prognosis, because it can take months for Oncophage to recharge the immune system, and the sickest patients might not have that much time, Armen said.
Antigenics was founded in 1994 and had an accumulated deficit of $470.5 million through March 31, according to the company's first-quarter earnings report to the U.S. Securities and Exchange Commission.
The company's stock has mirrored the ups and downs of Seattle-based Dendreon Corp., another developer of immune- stimulating therapies for cancer. Antigenics stock rose 12 percent on March 30, after Dendreon received a positive recommendation from an FDA advisory panel.
Antigenics shares then dropped 12 percent on May 9, when the FDA asked Dendreon to provide more information to show its prostate cancer treatment is effective.
To contact the reporter on this story: Luke Timmerman in San Francisco ltimmerman@bloomberg.net .
Last Updated: May 21, 2007 12:19 EDT
Email this article Printer friendly format
Advertisement: A surprising prediction by Ken Fisher - Get his forecast here!
lmao
Ditto! I figured it would pop after AVNR and DNDN also. AVNR moved on Short Covering alone and their Financials came out Sat. I called AGEN on Friday at 2.38 that it began upticking and a relatively big purchase went through Fri. morning. I flipped position from Friday and re-entered . I will hold overnight since this has some legs yet. It had bottomed after about 3 weeks of getting hammered mostly because DNDN news brought massive shorts in.
AGEN:I agree.. Bloomberg is one of the 4M short or on the Naked Sho List. They clobberred for the last 3 weeks.
Plus you don't get to a Phase III with all fabricated data. Now a Phase I could be a different story.
Flipped it. No more longterm bets here. Shorts will probably drive down a little yet. May re-enter.
I called on Friday on another bd. when it began to uptick. 4+ M short and on Naked Short list.
AGEN - I called on FRIDAY. Nice entry at 2.38.